Abstract
Abstract One of the major complications of anti-VEGF-A (vascular endothelial growth factor-A) agents are their serious hematological toxicities. We had earlier shown that the catecholamine neurotransmitter dopamine is a potent inhibitor of VEGF-A induced tumor angiogenesis and thereby, tumor growth. Therefore, it is prudent to investigate the effects of dopamine on important hematological parameters in preclinical cancer models. Our study shows that in addition to inhibiting tumor angiogenesis and growth of colon and prostate cancer bearing animals, dopamine can also significantly improve hemoglobin concentration, RBC and platelet counts in these animals. Anemia and thrombocytopenia are the two most common hematological toxicities induced by anti-VEGF-A drugs, which in turn increases the morbidity in cancer patients treated with these agents. Our report here shows that the anti-angiogenic action of dopamine inhibits tumor angiogenesis and growth in preclinical models without adversely affecting hematopiesis; rather it ameliorates anemia associated with cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4263. doi:10.1158/1538-7445.AM2011-4263
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
